GSK reports promising early results GSK has shared early trial results for Mo Rez , a drug being developed for ovarian and “womb” (endometrial) cancers. In the reported findings, the treatment reduced or eliminated tumors in more than 60% of patients , and GSK said the drug is expected to become a…
Continue reading...
Continue reading...